

Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease

Manuel Gorostidi^{1*}, Rafael Santamaría^{2*}, Roberto Alcázar³, Gema Fernández-Fresnedo^{4*}, Josep M. Galcerán⁵, Marián Goicoechea⁶, Anna Oliveras^{7*}, José Portolés^{8*}, Esther Rubio⁸, Julián Segura^{9*}, Pedro Aranda^{10*}, Ángel L.M. de Francisco^{4*}, M. Dolores del Pino¹¹, Francisco Fernández-Vega¹, José L. Górriz^{12*}, José Luño⁶, Rafael Marín¹³, Isabel Martínez¹⁴, Alberto Martínez-Castelao¹⁵, Luis M. Orte¹⁶, Carlos Quereda^{16*}, José C. Rodríguez-Pérez^{17*}, Mariano Rodríguez^{2*}, Luis M. Ruilope^{9*}

¹ Hospital Universitario Central de Asturias. Oviedo; ² Hospital Universitario Reina Sofía. Córdoba; ³ Hospital Universitario Infanta Leonor. Madrid; ⁴ Hospital Universitario Marqués de Valdecilla. Santander, Cantabria; ⁵ Fundació Althaia. Manresa, Barcelona; ⁶ Hospital General Universitario Gregorio Marañón. Madrid; ⁷ Hospital Universitari del Mar. Barcelona; ⁸ Hospital Universitario Puerta de Hierro. Madrid; ⁹ Hospital Universitario 12 de Octubre. Madrid; ¹⁰ Hospital Universitario Carlos Haya. Málaga; ¹¹ Hospital Universitario Torrecárdenas. Almería; ¹² Hospital Universitario Dr. Peset. Valencia; ¹³ Centro Médico de Asturias. Oviedo; ¹⁴ Hospital de Galdakao. Bilbao, Vizcaya; ¹⁵ Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona; ¹⁶ Hospital Universitario Ramón y Cajal. Madrid; ¹⁷ Hospital Universitario Dr. Negrín. Las Palmas de Gran Canaria. (Spain). * Red de Investigación Renal (REDinREN)

Nefrologia 2014;34(3):302-16

doi:10.3265/Nefrologia.pre2014.Feb.12464

ABSTRACT

The new Kidney Disease: Improving Global Outcomes (KDIGO) international guidelines on chronic kidney disease (CKD) and the management of blood pressure (BP) in CKD patients are an update of the corresponding 2002 and 2004 KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines. The documents aim to provide updated guidelines on the assessment, management and treatment of patients with CKD. The first guidelines retain the 2002 definition of CKD but present an improved prognosis classification. Furthermore, concepts about prognosis of CKD, recommendations for management of patients, and criteria for referral to the nephrologist have been updated. The second guideline retains

the <130/80mmHg-goal for management of BP in patients with CKD presenting increased albuminuria or proteinuria (albumin-to-creatinine ratio 30-300 mg/g, and >300 mg/g, respectively) but recommends a less-strict goal of <140/90mmHg in patients with normoalbuminuria. The development of the guidelines followed a predetermined process in which the evidence available was reviewed and assessed. Recommendations on management and treatment are based on the systematic review of relevant studies. The GRADE system (Grading of Recommendations Assessment, Development and Evaluation) was used to assess the quality of evidence and issue the grade of recommendation. Areas of uncertainty are also discussed for the different aspects addressed.

Correspondence: Manuel Gorostidi
Hospital Universitario Central de Asturias.
Celestino Villamil, s/n. 33006 Oviedo. (Spain).
manuel.gorostidi@gmail.com

Keywords: Albuminuria. Chronic kidney disease. Classification. Glomerular filtration rate. Clinical practice guideline. Hypertension. KDIGO. Proteinuria. Evidence-based recommendation. Systematic review.

Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica

RESUMEN

Las nuevas guías internacionales del consorcio KDIGO (Kidney Disease: Improving Global Outcomes) sobre la enfermedad renal crónica (ERC) y sobre el manejo de la presión arterial (PA) en pacientes con ERC constituyen la actualización de las correspondientes guías KDOQI (Kidney Disease Outcomes Quality Initiative) de 2002 y 2004. El objetivo de estos documentos es ofrecer una guía actualizada para el diagnóstico, la evaluación, el manejo y el tratamiento del paciente con ERC. La primera guía conserva la definición de ERC de 2002, pero ofrece una clasificación pronóstica mejorada. Además, se revalúan los conceptos sobre el pronóstico de la ERC, y se establecen recomendaciones para el manejo de los pacientes y sobre los criterios de derivación al especialista en nefrología. La segunda guía conserva el objetivo de una PA < 130/80 mmHg para pacientes con ERC que curse con una albuminuria elevada (cociente albúminal creatinina en muestra aislada de orina entre 30 y 300 mg/g) o proteinuria (cociente albúminal creatinina en muestra aislada de orina > 300 mg/g), pero recomienda el objetivo menos estricto de PA < 140/90 mmHg para pacientes con albuminuria normal. El desarrollo de las guías siguió un proceso predeterminado de revisión y evaluación de las evidencias disponibles. Las recomendaciones sobre el manejo y el tratamiento están basadas en la revisión sistemática de los estudios relevantes. El sistema GRADE (Grading of Recommendations Assessment, Development and Evaluation) se utilizó para evaluar la calidad de la evidencia y emitir el grado de recomendación. También se discuten las áreas de incertidumbre de los distintos aspectos tratados.

Palabras clave: Albuminuria. Enfermedad renal crónica. Clasificación. Filtrado glomerular. Guía de práctica clínica. Hipertensión arterial. KDIGO. Proteinuria. Recomendaciones basadas en la evidencia. Revisión sistemática.

INTRODUCTION

The epidemiological view of chronic kidney disease has experienced a significant change in the last twenty years. Initially restricted to relatively low incidence pathologies, such as glomerular diseases or hereditary nephropathies, and to a specialised care setting (Nephrology), CKD that is

predominant today affects a large percentage of the population and is related to highly prevalent diseases or phenomena, such as old age, high blood pressure (HBP), diabetes or cardiovascular disease. CKD is often a comorbidity suffered by patients followed up by many medical specialties, particularly Primary Care, Internal Medicine, Cardiology, Geriatrics, Endocrinology and any other medical or surgical specialty in which patients at risk of developing CKD are treated, especially those related to old age. Advanced CKD patients included in renal replacement therapy programmes using dialysis and transplantation are considered the visible part of the iceberg that is the major public health problem of CKD in the population.

In the last ten years, scientific nephrology societies have worked hard to collect information on CKD and research this disease. In 2002, the US National Kidney Foundation published K/DOQI (Kidney Disease Outcome Quality Initiative)^{1,2} guidelines, which established the current definition of CKD, the classification into grades and the basic assessment methods, such as renal function estimation using equations to calculate the glomerular filtration rate (GFR) based on the determination of serum creatinine and the assessment of albuminuria using the albumin/creatinine ratio in an isolated urine sample. In 2004, the first K/DOQI guidelines on HBP management in CKD patients were published³. The K/DOQI CKD classification was included in the first Spanish Society of Nephrology (S.E.N.) guidelines that were published after this time^{4,5}. In 2003, the Kidney Disease Improving Global Outcomes (KDIGO) organisation was founded as an international and independent expert group, with Spanish participation, in order to develop initiatives for the prevention and management of CKD (<http://www.kdigo.org/>). The first guidelines on the definition and classification of CKD were published in 2005 and they endorsed the approach of the 2002 K/DOQI guidelines⁶. In 2008, the S.E.N. and the Spanish Society of Family and Community Medicine (semFYC) developed the S.E.N.-semFYC CKD Consensus Document, which established the bases for joint management and prevention of kidney disease between Primary Care and Nephrology⁷. The S.E.N. developed a very extensive CKD training and research activity programme⁸, one of the main exponents of which is the EPIRCE (Epidemiological Study of Renal Failure in Spain) study, which revealed a CKD prevalence of 9.16% in the general population⁹. In parallel, the main international and national guidelines on hypertensive patient management incorporated this CKD diagnostic system and included a decrease in renal function and albuminuria amongst the main cardiovascular risk variables^{10,11}. Lastly, in recent months, a CKD consensus document promoted by the S.E.N. was published by ten Spanish scientific societies¹². In this context, new KDIGO guidelines were published in December 2012 and January 2013 on the assessment and treatment of CKD and on antihypertensive treatment in patients with this disease^{13,14}, the full version of which is available free at <http://www.kdigo.org/>.

special articles

org. The objective of the present article was to create a short, practical document that includes the main points of these two latest KDIGO guidelines.

METHODOLOGY

The recommendations on the management and treatment of CKD expressed in the abovementioned KDIGO guidelines were based on the systematic review of relevant studies by working groups of international nephrology experts and a team of experts in evidence-based medicine. The resulting manuscripts were subject to a public review. Those who carried out this review appear in the corresponding appendices of the guidelines. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) system was used to assess the quality or level of evidence and issue the grade of recommendation (GR). Appendix 1 displays the GRADE system definitions used by the KDIGO group.

The present document, which includes the aforementioned KDIGO guidelines, was prepared using the following methodology. A drafting committee prepared summaries of the guideline chapters by subject area. The summaries were compiled by special editors and the resulting manuscript was revised by an expert committee appointed by the S.E.N. After collecting expert contributions, a definitive document was prepared, which was submitted for the approval of all the

authors. Appendix 2 displays the distribution of authors in the different working groups.

This document summarises the aspects of the aforementioned KDIGO guidelines that refer to adult CKD patients in stages before renal replacement therapy, with the exception of HBP management in kidney transplant patients. Furthermore, the document aims to provide a holistic perspective on these and other daily clinical practice guidelines. The level of evidence and the GR are expressed with “we recommend” for a level 1 recommendation (most patients should receive the recommended action) and “we suggest” for the level 2 recommendation (many patients should receive the recommended action, although a significant percentage of cases may be subject to another approach). The authors of this document highlight the current small amount of grade A evidence and level 1 recommendations in the KDIGO guidelines and consider that many CKD aspects are the subject of debate. The GR and the corresponding evidence level of the main recommendations are displayed in brackets.

DEFINITION OF CHRONIC KIDNEY DISEASE

CKD is defined as abnormalities of kidney structure or function, present for at least three months with implications for health (GR, not graded). This definition is the same as

ADDENDUM 1. GRADE system

Levels of evidence

Grade	Quality of evidence	Explanation
A	High	We are confident that the real effect is close to the anticipated effect
B	Moderate	It is likely that the real effect is close to the anticipated effect, but it may be different
C	Low	The real effect may be significantly different to the anticipated effect
D	Very low	The anticipated effect is very uncertain and is frequently incorrect

Grades of recommendation

Grade	Expression	Explanation
Level 1	We recommend	Most patients should receive the recommended action
Level 2	We suggest	Many patients should receive the recommended action, although in a significant percentage, a different approach may be used
Not graded	In general, this expression is used for recommendations based on common sense and in subjects in which the application of evidence is not adequate	

GRADE: Grading of Recommendations Assessment, Development and Evaluation.

ADDENDUM 2. Working group for the creation of this document**Special editors**

Gorostidi M, Santamaría R

Drafting committee (by alphabetical order)

Alcázar R, Fernández-Fresnedo G, Galcerán JM, Goicoechea M, Gorostidi M, Oliveras A, Portolés J, Rubio E, Santamaría R, Segura J

Expert committee (by alphabetical order)

Aranda P, de Francisco ALM, del Pino MD, Fernández-Vega F, Górriz JL, Luño J, Marín R, Martínez I, Martínez Castela A, Orte LM, Quereda C, Rodríguez-Pérez JC, Rodríguez M, Ruilope LM

the previous definition^{1,2,6,7}, except for the added phrase “with implications for health”, which reflects the concept that there may be certain abnormalities of kidney structure or function that do not have prognostic consequences (for example, a simple renal cyst). CKD diagnosis criteria are kidney damage markers or a GFR of less than 60ml/min/1.73m² (Table 1). Duration of more than three months of any of these abnormalities may be confirmed prospectively or be deduced from previous registries.

Chronic kidney disease categories or grades

After the diagnosis is confirmed, CKD is classified according to the GFR and albuminuria categories and the

aetiology (GR 1B). The cause of CKD is established according to the presence or absence of a systemic disease with potential kidney involvement or through observed or suspected pathological abnormalities (GR, not graded). The GFR (G1 to G5) and albuminuria (A1 to A3) grades are displayed in Table 2 (GR, not graded).

With respect to the previous CKD classification^{1,2,6,7}, 60ml/min/1.73 m² is retained as the threshold for defining the GFR and grade 3 is subdivided into G3a and G3b, according to whether the GFR is between 59 and 45 or between 44 and 30ml/min/1.73m², respectively. Furthermore, albuminuria should be classified in any GFR grade. It is also recommended to replace the term “microalbuminuria” for “moderately increased albuminuria”. Albuminuria is classified as A1, A2 or A3 according to the albumin/creatinine ratio in an isolated urine sample for values <30, 30-300 or >300mg/g, respectively (or according to the corresponding urine albumin excretion values displayed in Table 2).

The reaffirmation of considering a GFR <60ml/min/1.73m² as the value for defining CKD has been the subject of debate, particularly in older patients, given the reduction in GFR associated with age. This limit is based on results of the CKD Prognosis Consortium meta-analysis¹⁵⁻¹⁷. This study demonstrated the association between a GFR <60ml/min/1.73m² and the risk of overall mortality, cardiovascular mortality, CKD progression, progression to stage 5 CKD and acute renal failure, both in the general population and in high cardiovascular risk groups. Furthermore, the risk of nephrotoxicity due to drugs and metabolic and endocrinological complications exponentially increases with a GFR <60ml/min/1.73m².

Table 1. Chronic kidney disease diagnosis criteria

CKD is defined as abnormalities of kidney structure or function, present for more than 3 months

Criteria for CKD (either of the following present for >3 months)

Markers of kidney damage	Increased albuminuria
	Urine sediment abnormalities
	Electrolyte and other abnormalities due to tubular disorders
	Structural abnormalities detected by histology
	Structural abnormalities detected by imaging
Decreased GFR	Kidney transplantation
	GFR <60ml/min/1.73m ²

Grade of recommendation: not graded.

CKD: chronic kidney disease, GFR: glomerular filtration rate.

special articles

Table 2. Classification into chronic kidney disease grades

CKD classification is based on the cause^a and on the categories of GFR and albuminuria

GFR categories		
Category	GFR ^b	Description
G1	≥90	Normal or increased
G2	60-89	Mildly decreased
G3a	45-59	Mildly to moderately decreased
G3b	30-44	Moderately to severely decreased
G4	15-29	Severely decreased
G5	<15	Renal failure
Albuminuria categories		
Category	A/C ratio ^c	Description
A1	<30	Normal to mildly increased
A2	30-300	Moderately increased
A3	>300	Highly increased ^d

Grade of recommendation: although the division into GFR and albuminuria sections is a recommendation that is not graded, the recommendation of classifying CKD into GFR and albuminuria grades is considered level 1B.

A/C: albumin/creatinine, CKD: chronic kidney disease, GFR: glomerular filtration rate.

^a The cause will be established according to the presence or absence of a systemic disease or according to an observed or suspected pathological diagnosis; ^b GFR, glomerular filtration rate, in ml/min/1.73m²; ^c Albuminuria in the table is expressed as an albumin/creatinine ratio in mg/g in an isolated urine sample as the most recommended test; the equivalents in mg/mmol are A1 <3, A2 3-30 and A3 >30, and in albuminuria in 24 hour urine are A1 <30, A2 30-300 and A3 >300mg/24 hours; ^d This category includes the nephrotic syndrome, in which albuminuria is usually >2200mg/g (>2200mg/mmol or >2200mg/24 hours).

Risk stratification

The variables that determine risk of CKD complications are the causes of the latter, e.g., GFR grade, albuminuria grade and other risk factors or comorbidities. Upon diagnosing CKD in a specific patient, the aetiology should be explained along with the GFR and albuminuria grades, for example: G3a A3 CKD probably secondary to diabetic nephropathy for a diabetic patient with a GFR between 45 and 59ml/min/1.73m² and albuminuria >300mg/g. This system allows the prognostic classification of CKD patients in situations of moderate, high or very high risk with respect to the baseline or reference risk of patients without CKD laboratory criteria (GFR >60ml/min/1.73m² and albuminuria <30mg/g). Figure 1 displays the CKD risk stratification table according to GFR and albuminuria categories (GR, not graded).

ASSESSMENT OF CHRONIC KIDNEY DISEASE

The basic objective of the approach in CKD patients is to assess chronicity, the cause, the GFR and albuminuria. Chronicity is verified retrospectively, reviewing the previous history, or prospectively, whenever there are no previous laboratory tests. The cause is determined by the presence or absence of a systemic disease with

potential renal involvement or observed or suspected pathological abnormalities. Furthermore, a family history of the disease, sustained intake of nephrotoxic drugs and environmental factors, such as contact with metals like lead or mercury are assessed and imaging tests are performed.

GFR is assessed using a serum creatinine test and a formula for estimating the GFR (GR 1A). Serum creatinine is determined using a specific test with adequate traceability for international reference standards and with minimal deviation with respect to the isotope dilution mass spectrometry reference method. This recommendation does not vary with respect to that of previous documents^{1,7,18}. The new guidelines recommend changing the equation for estimating GFR to the 2009 CKD-EPI (CKD Epidemiology Collaboration) formula¹⁹ (GR 1B). GFR estimation using formulas based on serum creatinine may be less accurate in certain circumstances, such as in individuals who follow special diets (strict vegetarian or hyperprotein), those with major abnormalities in muscle mass (amputations, diseases with loss of muscle mass), those with extreme body mass indexes (<19kg/m² or >35kg/m²) or those who are pregnant. In these circumstances and in certain situations in which it is necessary to optimise GFR assessment (for example, assessment of potential kidney donors, patients with an estimated GFR of between 45 and

KDIGO 2012			Albuminuria		
			Categories, description and ranges		
Glomerular filtration rate Categories, description and ranges (ml/min/1,73 m ²)			A1	A2	A3
			Normal to mildly increased	Moderately increased	Severely increased
			< 30 mg/g ^a	30-300 mg/g ^a	> 300 mg/g ^a
G1	Normal or increased	≥90			
G2	Mildly decreased	60-89			
G3a	Mildly to moderately decreased	45-59			
G3b	Moderately to severely decreased	30-44			
G4	Severely decreased	15-29			
G5	Renal failure	<15			

Figure 1. Prognosis of chronic kidney disease according to the glomerular filtration rate and albuminuria categories.

Risk of specific kidney disease complications, risk of progression and cardiovascular risk: green, reference risk, there is not kidney disease if there are no other defining markers; yellow, moderate risk; orange, high risk; red, very high risk.

KDIGO: Kidney Disease: Improving Global Outcomes.

^a Albuminuria is expressed as an albumin/creatinine ratio.

59ml/min/1.73m² without other markers of kidney damage or patients who require treatments with high renal toxicity), it is suggested to test cystatin C and the estimated GFR using a cystatin C-based equation (preferably CKD-EPI cystatin) or assess creatinine clearance after urine collection over a given period of time. Furthermore, in situations of severe sodium and water retention (cirrhosis with fluid retention, congestive heart failure, advanced hypothyroidism), as well as in any severe situation with haemodynamic instability, it is not appropriate to estimate the GFR using a serum creatinine-based equation.

Albuminuria is initially assessed through an isolated urine sample (first urine of the morning), using the albumin/creatinine ratio (GR 2B). In the case of advanced albuminuria grades, the protein/creatinine ratio offers a more accurate view of proteinuria, although this test is not routinely carried out in our setting. Classic test strips are also considered as a screening method. An albumin/creatinine ratio ≥30mg/g is confirmed with a second sample. The quantification of urinary albumin or protein excretion over a certain period of time, for example, the classic 24-hour urine test, is reserved for special cases in which a more precise estimation is considered to be necessary. The classic term **microalbuminuria** should not be used (GR, not graded), with albuminuria being expressed in the aforementioned grades A1, A2 or A3. In any case, albuminuria should be considered as such in the absence of incidental factors that may increase it, such as urine infections, physical exercise, fever or heart failure.

PROGRESSION OF CHRONIC KIDNEY DISEASE

The progression and evolution of CKD varies a lot between patients. Since we do not have sufficient evidence to define and identify those who have rapid progression, the recommendation is to simultaneously and systematically assess the estimated GFR and albuminuria. Both the reduction of the GFR and the grade of albuminuria influence prognosis and have a synergistic effect (Figure 1)¹⁵⁻¹⁷.

CKD progression is defined as a sustained decrease in the GFR of >5ml/min/1.73m² per year or a change of category (from G1 to G2, from G2 to G3a, from G3a to G3b, from G3b to G4 or from G4 to G5) whenever the latter is accompanied by a GFR loss of ≥5ml/min/1.73m² (GR, not graded). Small fluctuations in the GFR do not necessarily indicate progression. Whenever the aforementioned progression criteria are detected, it is necessary to rule out potentially reversible exacerbation factors (progression versus exacerbation), such as obstructive uropathy, volume depletion, situations of haemodynamic instability or use of non-steroidal anti-inflammatory drugs, cyclooxygenase 2 inhibitors, nephrotoxic antibiotics, radiocontrast agents or renin-angiotensin system (RAS) blockers in certain haemodynamic conditions. In the case of progression, the aim is to identify progression factors, such as CKD aetiology, age, sex, race, smoking habits, obesity, HBP, hyperglycaemia, dyslipidaemia, previous cardiovascular disease and exposure to nephrotoxic agents and those that can be altered will be treated^{20,21}. Patients with progressive CKD

special articles

also have a higher cardiovascular risk and as such, they are suitable for the appropriate prevention measures.

The frequency of CKD patient monitoring is also subject to recommendation. As such, the frequency of check-ups is also based on the risk stratification table (Figure 1). In general terms, low-risk patients will be reviewed annually, moderate-risk patients will be reviewed every six months and high and very high-risk patients should be reviewed three, four or more times a year. This regimen is valid for stable patients. Regular repetition of the kidney function parameters is also useful for optimising the assessment of disease progression.

PREVENTING PROGRESSION AND MANAGING COMPLICATIONS OF CHRONIC KIDNEY DISEASE

The most common complications of CKD and their prevalence according to GFR grades are displayed in Table 3^{22,23}. The comprehensive management of cardiorenal risk patients forms the basis of CKD progression prevention. Although different nuances may be established between CKD progression prevention measures and cardiovascular prevention measures, the bases for overall prevention are dietary and lifestyle changes, HBP control, RAS blockade and metabolic (mainly glycaemic and lipid) control.

General recommendations for managing high blood pressure

Adequate blood pressure (BP) control is the basis for cardiovascular, renal and overall prevention in CKD patients.

The BP control target is <140/90mmHg in patients with an albumin/creatinine ratio <30mg/g, whether or not they are diabetics (GR 1B), and <130/80mmHg in patients with an albumin/creatinine ratio ≥30mg/g, both in non-diabetics and diabetics alike (GR 2D). The previous BP target <130/80 mmHg for all CKD patients, independently of the level of albuminuria or proteinuria, was a recommendation based particularly on observational data. However, recent data have questioned whether this target is beneficial for patients with CKD and albuminuria <30mg/g^{24,25}, and as such, it has been proposed that the targets recommended for hypertensive patients in general be applied to CKD patients with normal albuminuria. With regard to patients with increased albuminuria or proteinuria, the suggested BP target <130/80mmHg is recognised as an expert recommendation. The BP control target in CKD patients continues to be the subject of debate²⁶. In fact, three recent guidelines recommend BP control <140/90mmHg for hypertensive patients in general, including CKD patients²⁷⁻²⁹.

Achieving these targets is based on an individualised approach that includes non-pharmacological measures (changes in lifestyle) and pharmacological treatment. The introduction of lifestyle changes may reduce BP figures simply, cheaply and effectively and is usually accompanied by other beneficial effects^{30,31}. With regard to pharmacological treatment, the choice of drugs that must be used should be individualised according to age, tolerance and patient comorbidities. RAS blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) form the basis of pharmacological antihypertensive treatment in both non-diabetic and diabetic patients with an albumin/creatinine ratio ≥30mg/g. This type of drug is suggested

Table 3. Prevalence of common complications of chronic kidney disease according to the glomerular filtration grades^a

Complication	Glomerular filtration rate (ml/min/1.73m ²)				
	≥ 90	60-89	45-59	30-44	< 30
HBP ^b	18.3	41.0	71.8	78.3	82.1
Anaemia ^c	4.0	4.7	12.3	22.7	51.5
Hyperparathyroidism ^d	5.5	9.4	23.0	44.0	72.5
Hyperphosphataemia ^e	7.2	7.4	9.2	9.3	23.0
Deficiency of 25(OH) Vit D ^f	14.1	9.1	10.7		27.2
Acidosis ^g	11.2	8.4	9.4	18.1	31.5
Hypoalbuminaemia ^h	1.0	1.3	2.8	9.0	7.5

References: Levin et al.²² and Inker et al.²³.

HBP: high blood pressure.

^a Data in percentages; ^b Defined as systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg or use of antihypertensive medication; ^c Defined as levels of haemoglobin <12g/dl in females and <13.5g/dl in males; ^d Defined as intact parathyroid hormone ≥70pg/ml (≥7.4pmol/l); ^e Defined as serum phosphorus ≥4.5mg/dl (≥1.5mmol/l); ^f Defined as serum levels <15ng/ml (<37nmol/l); ^g Defined as serum bicarbonate <21mEq/l; ^h Defined as serum albumin <3.5g/dl.

as the first choice in patients with an albumin/creatinine ratio between 30 and 300mg/g (GR 2D), while in patients with an albumin/creatinine ratio >300mg/g, or equivalent proteinuria (>500mg/24 hours), it is recommended (GR 1B). Independently of the type of drug chosen as the first line of treatment, most patients will require more than one antihypertensive drug for adequate control of HBP. With regard to dual blockade using ACE inhibitors and ARBs, there is not enough evidence to recommend this combination in the prevention of CKD progression, but there is with regard to potential adverse effects, such as acute deterioration of kidney function or hyperkalaemia. Table 4 displays the key aspects of HBP management in CKD patients. A comprehensive review of the preferential indications, dose, adverse effects and contraindications of the different types of antihypertensive drugs are not included in the objectives of these guidelines. However, Table 5 summarises some of the basic aspects of each antihypertensive drug group.

Management of high blood pressure in elderly patients

Despite the high prevalence of HBP and CKD in individuals ≥ 65 years of age and especially in very elderly individuals (≥ 80 years of age), there is not enough evidence to develop recommendations on their management³². Antihypertensive treatment in this type of patient involves particular step therapy and monitoring of potential adverse effects, such as electrolyte imbalances, renal failure aggravation and orthostatic hypertension (GF, not graded). A strict control of BP and the use of RAS blockers, which are key in managing adult CKD patients, may not have the same benefits for very elderly patients, and may even have harmful effects³³. In the latter, there is no evidence to establish recommendations, and as such, their management should be particularly individualised³⁴.

Management of high blood pressure in kidney transplant patients

HBP in transplant patients is a risk factor for cardiovascular graft function deterioration³⁵. It is suggested that kidney transplant patients with BP >130/80mmHg be treated with the aim of maintaining BP <130/80mmHg independently of the level of urine albumin excretion (GR 2D). The choice of antihypertensive drug must take into account the time since transplantation, the presence or absence of increased albuminuria, use of calcineurin inhibitors and the presence of other comorbidities. When less than two years have elapsed since transplantation, calcium antagonists may have a beneficial effect added to the placebo effect or that of RAS blockers³⁶, with dihydropyridine calcium antagonists being preferable. During the first months after transplantation, RAS blockers may have a harmful effect on kidney function recovery. However, this may subsequently be the drug type of

choice, particularly in patients with increased urine albumin or protein excretion.

Cardiovascular risk in chronic kidney disease

CKD patients, particularly those with grades 3a to 5, have an increased cardiovascular risk corresponding to the accumulation of classic factors such as HBP or diabetes, and as such, they must be considered as high cardiovascular risk patients (GR 1A). Elevated albuminuria increases the risk independently of the GFR³⁷. The risk of having a major cardiovascular complication increases from 43% in CKD grade 3a to >300% in grades 4-5 with respect to individuals without CKD³⁸. In fact CKD patients have a greater risk of cardiovascular mortality than requiring renal replacement therapy via dialysis or renal transplantation³⁹. For these reasons, it is recommended to consider any individual with an estimated GFR <60ml/min/1.73m² as a high cardiovascular risk patient. There must be a comprehensive and structured plan for CKD patients for reducing cardiovascular risk, which must include abstaining from smoking, exercise, weight control, lipid profile control, optimal control of diabetes and BP, anaemia correction, phosphorus-calcium metabolism control and platelet anti-aggregation in secondary prevention. It is also advised for patients with CKD and an acute coronary event to receive the same level of diagnostic and therapeutic intervention as those without CKD (GR 1A). With regard to treatment of patients with CKD and heart failure, a similar level of intervention is suggested to that of patients without CKD (GR 2A), although any increase in treatment or any clinical deterioration must be accompanied by a stricter control of kidney function and serum potassium. Some diagnostic tests, such as those of troponins or BNP/NT-proBNP (B-type natriuretic peptide/N-terminal-proBNP), should be interpreted with caution in CKD patients, particularly those with an estimated GFR <60ml/min/1.73m², since the standard reference values may not have the same significance as in patients without CKD.

Nutritional and metabolic control

Control of obesity is a main objective in treating CKD patients, both as a measure of cardiovascular and overall prevention and to slow down renal failure progression (GR 1D).

A reduction in salt intake to between 4 and 6g per day is recommended, unless contraindicated (GR 1C).

High dietary protein intake in CKD patients results in an accumulation of uraemic toxins, but insufficient intake may lead to malnutrition. It is suggested to reduce protein intake to 0.8g/kg/day in adults with an estimated GFR <30ml/min/1.73m² (CKD grades 4-5) without evidence or risk of malnutrition (GR 2C).

special articles

Table 4. Key aspects of high blood pressure management in chronic kidney disease

Adequate control of BP forms the basis of cardiovascular and renal prevention in CKD patients	
Objectives	
Target	Comments
BP <140/90mmHg	- In non-diabetics and in diabetics with an albumin/creatinine ratio <30mg/g; GR: 1, recommended; evidence B
BP <130/80mmHg	- In non-diabetics and in diabetics with an albumin/creatinine ratio ≥30mg/g; GR: 2, suggested; evidence D
Individualise	- Caution in older patients or those with many cardiovascular comorbidities; GR: not graded - Caution in patients with orthostatic hypotension; GR: not graded
Non-pharmacological treatment (changes in lifestyle)	
Intervention	Comments
Weight reduction (GR 1D)	- Effective measure for overall prevention - Different interventions, non-surgical or surgical, that lead to the reduction of systolic BP between 9 and 23mmHg - It may be effective in reducing albuminuria - Particularly effective in CKD grades 1 and 2 - Caution in stage 5 due to risk of malnutrition
Reduced salt intake (GR 1C)	- Recommend between 4 and 6g of salt per day - Moderate effectiveness, reduction in systolic BP of 4-5mmHg - Particularly indicated in cases of salt and water retention
Physical exercise	- There are no specific studies in CKD patients - In the hypertensive or cardiovascular risk population, it is effective in overall prevention - Recommend 3-5 weekly sessions of 30-60 minutes of aerobic exercise - Reduction in systolic blood pressure of 6mmHg
Other	- A restriction in alcohol consumption is effective in the hypertensive population in general - Quitting smoking is a key measure in overall prevention - In CKD patients, potassium, magnesium or fatty acid supplements are not recommended
Pharmacological treatment of choice	
Drugs	Comments
General consideration	- In most patients, it is necessary to use more than one antihypertensive drug to control BP
ACE inhibitors or ARBs	- In non-diabetic and diabetic patients with an albumin/creatinine ratio of 30-300mg/g; GR: 2, suggested; evidence D - In non-diabetic and diabetic patients with an albumin/creatinine ratio of >300mg/g (or equivalent proteinuria >500mg/24 hours); GR: 1, recommended; evidence B
All drugs	- In non-diabetic and diabetic patients with an albumin/creatinine ratio of <30mg/g

ARBs: angiotensin receptor blockers, CKD: chronic kidney disease, GR: grade of recommendation, ACE inhibitors: angiotensin-converting enzyme inhibitors, BP: blood pressure.

In diabetic patients, a glycated haemoglobin (HbA_{1c}) target <7% (GR 1A) is recommended, except in frail patients at risk of hypoglycaemia or with major comorbidities that may reduce life expectancy, for whom the HbA_{1c} target is between 7.5% and 8% (GR 2C). In very elderly and frail

patients, a more relaxed HbA_{1c} target of <8.5% may be considered⁴⁰.

With regard to hyperuricaemia treatment, it is considered that there is not enough evidence that supports or rejects the use

Table 5. Indications, additional benefits, caution and combined use of the different antihypertensive drug groups in chronic kidney disease patients

RAS blockers				
Type of drug	Indications	Additional benefits	Caution	Combined use
ACE inhibitors or ARBs	Increased albuminuria Proteinuria Heart failure Post-AMI	Reduction of intraglomerular pressure Reduction of albuminuria or proteinuria Reduction of fibrosis Vascular and cardiac remodelling	Hyperkalaemia Monitor kidney function and K ⁺ after starting treatment Use of NSAIDs Use of COX-2 inhibitors Combined use with other RAS blockers Bilateral stenosis of renal arteries Volume depletion	Restriction of salt Diuretics Calcium antagonists Beta blockers
Aldosterone blockers	Resistant HBP Heart failure Post-AMI	Reduction of albuminuria or proteinuria	Hyperkalaemia Monitor kidney function and K ⁺ after starting treatment Use of NSAIDs Use of COX-2 inhibitors	ACE inhibitors ARBs
Direct renin inhibitors	HBP	Reduction of albuminuria or proteinuria	As above Increased risk of complications in diabetic or CKD patients when combined with ACE inhibitors or ARBs	Diuretics Calcium antagonists
Diuretics				
Thiazides	HBP	Reduced risk of hyperkalaemia	They aggravate hyperglycaemia Replace with loop diuretic if GFR <50ml/min/1.73m ²	ACE inhibitors ARBs
Loop diuretic	HBP (short term)	Reduced risk of hyperkalaemia		
Potassium-sparing diuretics			Hyperkalaemia	
Calcium antagonists				
DHP	HBP Angina	Vasodilation		With ACE inhibitors or ARBs it decreases the risk of oedema
No DHP	HBP Angina Supraventricular tachycardia	Vasodilation Reduction of intraglomerular pressure Reduction of heart rate	They increase the levels of calcineurin inhibitor and mTOR inhibitors Do not use with beta blockers	
Beta blockers				
	Heart failure (bisoprolol, carvedilol and metoprolol) Post-AMI	Reduction of heart rate	Risk of bradycardia Do not use with non-DHP calcium antagonists	Diuretics ACE inhibitors ARBs DHP calcium antagonists
Others				
Centrally-acting alpha agonists	Resistant HBP		Reduce moxonidine dose if the GFR is <30ml/min/1.73m ²	Tiazidas
Alpha blockers	Prostatic hypertrophy		Orthostatic hypotension	Non-selective beta blockers Diuretics
Direct vasodilators			Salt and water retention Tachycardia	Beta blockers Diuretics

NSAIDs: non-steroidal anti-inflammatory drugs; ARBs: angiotensin receptor blockers; COX2: cyclooxygenase 2; DHP: dihydropyridines; CKD: chronic kidney disease; HBP: high blood pressure; AMI: acute myocardial infarction; ACE inhibitors: angiotensin-converting enzyme inhibitors; RAS: renin-angiotensin system.

special articles

of hypouricaemic drugs for slowing down CKD progression. However, it is indicated that in patients with CKD and symptomatic hyperuricaemia (uric acid lithiasis or gout), uric acid levels of less than 7mg/dl should be achieved. To achieve this target, patients are treated with xanthine oxidase inhibitors with doses adjusted according to kidney function. The reduction of uric acid below 7mg/dl could decrease cardiovascular risk and slow down CKD progression in patients with asymptomatic hyperuricaemia. Despite there being data in the literature that support this, there are no interventional studies with a sufficient sample for recommending the use of hyperuricaemic drugs with this objective⁴¹.

Patients with advanced CKD grades may require specific dietary advice simultaneously (salt, carbohydrates, proteins, potassium, phosphorus), and will receive specialised and individualised care (GR 1B).

ANAEMIA

Anaemia contributes significantly to the symptoms and quality of life of patients and has a major impact on the prognosis of CKD. Serum haemoglobin tests should be carried out at least once a year in patients with grades 3a and 3b and at least once every six months in patients with an estimated GFR <30ml/min/1.73m². The treatment and therapeutic targets mentioned are addressed in the corresponding guidelines⁴², although the key aspects include: 1) ruling out secondary causes, mainly iron deficiency, 2) giving patients iron supplements in cases of deficiency and 3) using erythropoiesis-stimulating agents with target haemoglobin not exceeding 11.5g/dl. Treatment with erythropoiesis-stimulating agents is not recommended in cases of active malignant disease. Basic studies on assessing anaemia in CKD patients include a complete blood count and testing levels of reticulocytes, serum ferritin, the transferrin saturation index, vitamin B12 and folate. The first step in treating anaemia associated with CKD is iron supplements if the transferrin saturation index is $\leq 30\%$ and serum ferritin is ≤ 500 ng/ml. Treatment with erythropoiesis-stimulating agents is assessed with haemoglobin levels <10g/dl⁴². The GR and levels of evidence corresponding to these considerations on anaemia in CKD are displayed in the corresponding KDIGO guidelines⁴².

MINERAL AND BONE METABOLISM DISORDERS

Mineral and bone metabolism disorders may begin at initial CKD grades and increase as the disease progresses (Table 3). These changes are grouped under the heading of mineral and bone metabolism disorders and include related renal osteodystrophy and extraskeletal (vascular) calcifications. Renal osteodystrophy in turn includes osteitis fibrosa cystica (hyperparathyroidism), osteomalacia and adynamic bone disease. The current KDIGO guidelines refer to the recommendations of the previous specific guidelines⁴³, which is also expressed in the corresponding S.E.N. guidelines⁴⁴. It

is advised to assess serum levels of calcium, phosphorus, alkaline phosphatase, intact parathyroid hormone (iPTH) and vitamin D (25 OH D₃) in patients with an estimated GFR <45ml/min/1.73m² (grades 3b to 5). In patients with these CKD grades, it is suggested to maintain phosphorus concentration within the normal range. The absence of evidence with regard to the optimal level of iPTH in these patients is recognised, and as such, if an increased iPTH level is detected in these patients, it is suggested to assess the possibility of hyperphosphataemia, hypocalcaemia and vitamin D deficiency. Table 6 displays the values of these parameters recommended in the S.E.N. guidelines for managing mineral and bone metabolism disorders in CKD patients not on dialysis⁴⁴. With regard to the indication of testing mineral and bone density metabolism and using bisphosphonates, it is suggested not to indicate bone density scans routinely in patients with an estimated GFR <45ml/min/1.73m² and to avoid the aforementioned prescription in patients with an estimated GFR <30ml/min/1.73m². The GR and levels of evidence corresponding to these considerations on mineral and bone density metabolism disorders in CKD are displayed in the corresponding KDIGO guidelines⁴³.

Acidosis

As with other aforementioned complications, the prevalence and severity of acidosis increases as CKD deteriorates (Table 3). Treatment with oral bicarbonate supplements in patients with bicarbonate concentrations <22mEq/l is suggested, if it is not contraindicated.

OTHER SAFETY ASPECTS IN CHRONIC KIDNEY DISEASE PATIENTS

CKD patients are vulnerable to certain very common situations in healthcare and they must therefore receive the appropriate preventive measures.

Risk of acute deterioration of kidney function

Kidney function deterioration worsens the prognosis of any acute or chronic pathology. It is recommended to consider all CKD patients as a population at risk of acute renal failure (GR 1A). This consideration should particularly be taken into account in cases of intercurrent disease and, above all, in any situation of hospitalisation or any diagnostic or therapeutic procedure.

Use of drugs in kidney disease patients

The main recommendations with regard to the use of drugs in CKD patients are: 1) use GFR for drug dose calculation

Table 6. Values recommended in the guidelines of the Spanish Society of Nephrology for managing mineral and bone metabolism disorders in chronic kidney disease patients not on dialysis

Parameter	Grade of CKD	Recommended values
Calcidiol	All	>30ng/ml
Calcium	All	8.4-9.5mg/dl (tolerance until 10mg/dl)
Phosphorus	All	2.5-4.5mg/dl
iPTH	Grade 3	35-70pg/ml
	Grades 4 and 5	70-110pg/ml

Reference: Torregrosa⁴⁴.

CKD: chronic kidney disease, iPTH: intact parathyroid hormone.

(GR 1A); 2) temporarily discontinue potentially nephrotoxic treatment or treatment that is preferentially eliminated via the kidneys in patients with an estimated GFR <60ml/min/1.73m² in circumstances of severe intercurrent disease, given the risk of acute function deterioration; the drugs that must be taken into account in this recommendation are mainly ACE inhibitors, ARBs, aldosterone antagonists, diuretics, non-steroidal anti-inflammatory drugs, metformin, lithium and digoxin (GR 1C); 3) do not use herbal medicine; 4) do not use metformin in patients with a GFR <45ml/min/1.73m²; and 5) monitor kidney function, electrolytes and drug levels in patients who receive potentially nephrotoxic drugs, mainly aminoglycoside antibiotics, lithium, calcineurin inhibitors and digoxin.

Use of radiological contrasts

In patients with a GFR <60ml/min/1.73m² who are going to receive an iodine contrast, it is recommended to avoid high osmolarity agents, use the minimum possible dose of the radiocontrast agent, discontinue potentially nephrotoxic drugs beforehand, particularly metformin, administer adequate hydration with saline solution before, during and after the procedure and monitor the GFR 48-96 hours after the latter (GR 1, A to C according to each specific recommendation). The use of N-acetylcysteine or ascorbic acid as prophylaxis for nephropathy due to iodine contrasts has not consistently demonstrated to be beneficial and as such, it has not been included as a recommendation in the KDIGO guidelines. However, the guidelines of the S.E.N. on acute renal failure recommend prophylaxis with N-acetylcysteine before the administration of the iodine contrast and it is assigned a B evidence level⁴⁵.

It is recommended to avoid the use of gadolinium-based contrasts in patients with an estimated GFR <15ml/min/1.73m² (GR 1B), except when there is no alternative. In patients with an estimated GFR <30ml/min/1.73m², it is

advised to avoid the use of gadodiamide and give preference to other preparations, such as gadoteridol, gadobutrol or gadoterate. Although the KDIGO guidelines do not make recommendations for dialysis patients, they recommend carrying out a dialysis session immediately after the procedure and probably also after 24 hours. The role of dialysis in patients with an estimated GFR <15ml/min/1.73m² who are not receiving renal replacement therapy is uncertain.

Likewise, it is recommended not to use oral preparations with phosphates for intestinal preparation in patients with an estimated GFR <60ml/min/1.73m² (GR 1A). It is currently debated whether the potential kidney damage is due to dehydration caused by these compounds more than by the phosphorus itself. For enemas, preparations without phosphate may be safer (fisioenema). For oral preparation, there are no phosphate-free preparations, and as such, it is recommended to avoid dehydration.

Vaccinations

Unless contraindicated, it is recommended to vaccinate against the flu in patients with a GFR <60ml/min/1.73m², against pneumococcal infection in patients with a GFR <30ml/min/1.73m² and in high risk cases such as patients with nephrotic syndrome, diabetes or those who receive immunosuppressive treatment, and against hepatitis B in cases with a GFR <30ml/min/1.73m² and risk of progression.

REFERRAL TO THE NEPHROLOGIST

Table 7 displays the criteria for referring CKD patients to Nephrology (GR 1B). Other situations may be managed by other doctors, mainly Family and Community Medicine specialists, who should regularly monitor patients, in accordance with that stated in the corresponding section. Figure 2 indicates the recommendations for monitoring or

special articles

referral in accordance with the CKD grade. These referral criteria are basically the same as those recommended in the aforementioned 2008 S.E.N.-semFYC consensus document on CKD of ten Spanish scientific societies^{7,12}.

Conflicts of interest

The authors declare that they have no conflicts of interest related to the contents of this article.

Table 7. Criteria for referral to the nephrologist

- Acute deterioration of kidney function
- GFR <30ml/min/1.73m²
- Significant and sustained albuminuria (albumin/creatinine ratio \geq 300mg/g; equivalent to protein/creatinine ratio \geq 500mg/g or proteinuria \geq 500mg/24h)
- CKD progression (sustained decrease in the GFR >5ml/min/1.73m² per year or due to a change of category [from G1 to G2, from G2 to G3a, from G3a to G3b, from G3b to G4 or from G4 to G5], whenever the latter is accompanied by a GFR loss of \geq 5ml/min/1.73m²)^a
- Microhaematuria not explained by other causes, sediment with >20 red blood cells/field, especially in the case of red blood cell casts
- Resistant HBP (not controlled with a combination of three antihypertensive drugs, including a diuretic)
- Persistent serum potassium abnormalities
- Recurrent nephrolithiasis
- Hereditary kidney disease

Grade of recommendation: 1, recommendation, evidence B.

CKD: chronic kidney disease, GFR: glomerular filtration rate, HBP: high blood pressure.

^a Small fluctuations in GFR do not necessarily indicate progression. When the abovementioned progression criteria are detected, it would be necessary to rule out potentially reversible exacerbation factors (progression versus exacerbation), such as obstructive uropathy, volume depletion, situations of haemodynamic instability or use of non-steroidal anti-inflammatory drugs, cyclooxygenase 2 inhibitors, nephrotoxic antibiotics, radiocontrast agents or renin-angiotensin system blockers in certain haemodynamic conditions.

Glomerular filtration rate Categories, description and ranges (ml/min/1,73 m ²)			Albuminuria		
			Categories, description and ranges		
			A1	A2	A3
	Normal to Mildly increased		Mildly increased		Severely increased
	<30 mg/g ^a		30-300 mg/g ^a		>300 mg/g ^a
G1	Normal or increased	\geq 90		Monitor	Refer
G2	Mildly decreased	60-89		Monitor	Refer
G3a	Mildly to moderately decreased	45-59	Monitor	Monitor	Refer
G3b	Moderately to severely decreased	30-44	Monitor	Monitor	Refer
G4	Severely decreased	15-29	Refer	Refer	Refer
G5	Renal failure	<15	Refer	Refer	Refer

Figure 2. Recommendations for the referral of chronic kidney disease patients to the nephrologist according to glomerular filtration rate and albuminuria categories.

Frequency of laboratory monitoring will be annual in principle for low-risk patients (green), once every six months for moderate-risk patients (yellow) and three or more times a year for high or very high-risk patients. This regimen is considered valid for stable patients.

^a Albuminuria is expressed as an albumin/creatinine ratio.

REFERENCES

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2 Suppl 1):S1-266.
2. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003;139:137-47.
3. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 2004;43(5 Suppl 1):S1-290.
4. Marín R, Goicoechea MA, Gorostidi M, eds. Guías SEN. Riñón y enfermedad cardiovascular. *Nefrología* 2004;24(Suppl 6):S1-235.
5. Marín R, Goicoechea M, Gorostidi M, Cases A, Díez J, Escolar G, et al.; en representación del Comité de Expertos de la Guía de la Sociedad Española de Nefrología. Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad vascular. Versión abreviada. *Nefrología* 2006;26:31-44.
6. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005;67:2089-100.
7. Alcázar R, Egocheaga MI, Orte L, Lobos JM, González Parra E, Álvarez Guisasaola F, et al. Documento de consenso SEN-semFYC sobre la enfermedad renal crónica. *Nefrología* 2008;28:273-82.
8. Alcázar R, de Francisco ALM. Acción estratégica de la SEN frente a la enfermedad renal. *Nefrología* 2006;26:1-4.
9. Otero A, de Francisco A, Gayoso P, García F, on behalf of the EPIRCE Study Group. Prevalence of chronic renal disease in Spain: Results of the EPIRCE study. *Nefrología* 2010;30:78-86.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007;25:1105-87.
11. De la Sierra A, Gorostidi M, Marín R, Redón J, Banegas JR, Armario P, et al. Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso. *Med Clin (Barc)* 2008;131:104-16.
12. Documento de consenso sobre la enfermedad renal crónica. Available at: http://www.senefro.org/modules.php?name=news&d_op=detail&idnew=1274.
13. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl* 2012;2:337-414.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 2013;3:1-150.
15. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073-81.
16. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* 2011;79:1341-52.
17. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int* 2011;80:93-104.
18. Gracia S, Montañés R, Bover J, Cases A, Deulofeu R, de Francisco ALM, et al. Documento de consenso: Recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos. *Nefrología* 2006;26:658-65.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604-12.
20. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. *JAMA* 2011;305:1553-9.
21. Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT. Development and validation of a general population renal risk score. *Clin J Am Soc Nephrol* 2011;6:1731-8.
22. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int* 2007;71:31-8.
23. Inker LA, Coresh J, Levey AS, Tonelli M, Muntner P. Estimated GFR, albuminuria, and complications of chronic kidney disease. *J Am Soc Nephrol* 2011;22:2322-31.
24. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1575-85.
25. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med* 2010;363:918-29.
26. Ruilope LM. Chronic kidney disease: Blood pressure control in CKD--still a matter of debate. *Nat Rev Nephrol* 2013;9:572-3.
27. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013;31:1281-357.
28. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014;311:507-20.
29. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American

special articles

- Society of Hypertension and the International Society of Hypertension. *J Hypertens* 2014;32:3-15.
30. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens* 2006;24:215-33.
 31. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009;4:1565-74.
 32. Fischer MJ, O'Hare AM. Epidemiology of hypertension in the elderly with chronic kidney disease. *Adv Chronic Kidney Dis* 2010;17:329-40.
 33. Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. *Clin J Am Soc Nephrol* 2010;5:1330-9.
 34. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *J Am Soc Hypertens* 2011;5:259-352.
 35. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. *Transplantation* 2006;82:603-11.
 36. Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. *Transplantation* 2004;78:1204-11.
 37. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001;286:421-6.
 38. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. *BMJ* 2006;333:1047.
 39. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 2004;164:659-63.
 40. Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E; en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Documento de consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. *Med Clin (Barc)* 2014;142(2):85.e1-10.
 41. Johnson R, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease. Which is chasing with? *Nephrol Dial Transplant* 2013;28:2221-8.
 42. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney Int Suppl* 2012;2:279-335.
 43. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int Suppl* 2009;(113):S1-130.
 44. Torregrosa JV, Bover J, Cannata J, Lorenzo V, de Francisco ALM, Martínez I, et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.-MM). *Nefrología* 2011;31 Suppl 1:3-32.
 45. Gainza FJ, Liaño F, editores especiales. Guías SEN. Actuación en el fracaso renal agudo. *Nefrología* 2007;27(Suppl 3):1-274.